Nitisinone

CAS 104206-65-7 4 current records 1 historicalSmall Molecule

Who holds supplier records for Nitisinone? 4 organisations hold a current record for Nitisinone: an active US FDA Type II Drug Master File. A further 1 organisation has only historical (inactive) DMF filings. Recorded organisation countries for current records: India (2), Switzerland (1) and United States (1).

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Nitisinone: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/nitisinone

Reading the evidence

  • 4 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • 2 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Nitisinone expires 5 Jan 2035. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (4)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Nitisinone. Country is the organisation's recorded country, not necessarily the manufacturing site.

Need Nitisinone sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Historical records (1)

Organisations whose Type II DMFs for Nitisinone are no longer active. These show a past filing, not current supply.

Show all 1 historical record

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (20 listed products contain Nitisinone). The latest listed patent expires 5 Jan 2035. The latest listed exclusivity runs to 10 Jun 2032. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Overview

Nitisinone is an inhibitor of the enzyme 4-Hydroxyphenylpyruvate dioxygenase used in the treatment of hereditary tyrosinemia type 1 (HT-1), a genetic disorder that can cause liver and kidney damage. It prevents the accumulation of toxic byproducts of tyrosine metabolism by blocking its catabolic pathway.

Chemical identity

IUPAC name
2-[2-nitro-4-(trifluoromethyl)benzoyl]cyclohexane-1,3-dione
Canonical SMILES
C1CC(=O)C(C(=O)C1)C(=O)C2=C(C=C(C=C2)C(F)(F)F)[N+](=O)[O-]
InChIKey
OUBCNLGXQFSTLU-UHFFFAOYSA-N
Synonyms
Orfadin API, nityr, ntbc, orfadin, sc-0735

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
4-Hydroxyphenyl-Pyruvate Dioxygenase Inhibitor
Mechanism of action
Cytochrome P450 2C9 Inhibitors; Cytochrome P450 2E1 Inducers; Hydroxyphenylpyruvate Dioxygenase Inhibitors; Organic Anion Transporter 1 Inhibitors; Organic Anion Transporter 3 Inhibitors

Therapeutic areas

Genetic DisordersMetabolic Disorders

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Nitisinone?

4 organisations hold an active US FDA Type II Drug Master File or a CEP for Nitisinone: BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (India), DIPHARMA SA (Switzerland), NOVITIUM PHARMA LLC (United States) and Scl Lifesciences Limited (India). A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Nitisinone Drug Master Files are active?

BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (DMF 33948), DIPHARMA SA (DMF 36026), NOVITIUM PHARMA LLC (DMF 31250) and Scl Lifesciences Limited (DMF 35810). The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Nitisinone records mean?

1 organisation has only inactive Type II DMFs for Nitisinone. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does the FDA Orange Book list patents for products containing Nitisinone?

Yes. The latest patent listed for an approved US product containing Nitisinone expires 5 Jan 2035, across 20 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Nitisinone supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Nitisinone?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.